Monte Rosa Therapeutics Appoints Jennifer Champoux as COO
Company Announcements

Monte Rosa Therapeutics Appoints Jennifer Champoux as COO

An announcement from Monte Rosa Therapeutics (GLUE) is now available.

Monte Rosa Therapeutics, Inc. has elevated Jennifer Champoux to Chief Operating Officer, recognizing her extensive experience in the biopharmaceutical industry. With a background that includes leading operations at H3 Biomedicine and a stint in Novartis Institutes, along with roles at Merck and Array BioPharma, Champoux’s promotion is based on merit and expertise. Her academic credentials include a Master’s in Chemistry, and her professional journey spans over 15 years, covering strategic planning, finance, and team culture. The company publicly announced her new role, emphasizing that there are no undisclosed arrangements behind her promotion or conflicts of interest involving company transactions.

For an in-depth examination of GLUE stock, go to TipRanks’ Stock Analysis page.

Related Articles
TheFlyBoeing to offer 90M common shares, Philips reports mixed Q3: Morning Buzz
TheFlyMonte Rosa Therapeutics price target raised to $20 from $16 at Piper Sandler
TipRanks Auto-Generated NewsdeskMonte Rosa Enters Global License Agreement with Novartis
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App